SENECA is a new unique cell therapy clinical trial that may be of interest to patients who are cancer survivors with left ventricular dysfunction secondary to anthracycline-induced cardiomyopathy (AIC).


The trial, called SENECA (StEm cell iNjEction in CAncer survivors), is being conducted by the Cardiovascular Cell Therapy Research Network (CCTRN), and funded by the National Heart, Lung, and Blood Institute).  It is designed to assess the safety, feasibility, and effect of delivering allogeneic mesenchymal stem cells (allo-MSCs) via transendocardial injection in cancer survivors diagnosed with AIC.  In this phase I study, we hypothesize that these cells will be well-tolerated, and when compared with placebo, will demonstrate trends toward scar reduction and improved cardiac performance, functional capacity, and quality of life.


Study population and criteria:


  • Patients who are cancer survivors with a diagnosis of AIC
  • Received initial AIC diagnosis at least 6 months ago
  • On stable optimally-tolerated heart failure therapy
  • Period of at least 2 years clinical cancer-free
  • Aged 18-79
  • Have an EF < 40%
  • NYHA class II or III
  • Are a candidate for cardiac catheterization


This multi-center study will be opening for enrollment very soon at seven locations across the country:  University of Louisville, Texas Heart Institute, University of Florida, University of Miami, Minneapolis Heart Institute Foundation, Stanford University, and Indiana University


To learn more about the trial, please see our posting (NCT02509156) on


To learn more about CCTRN Studies or to find recruiting locations for SENECA in your area, please visit:


We welcome your inquiries.


Lem Moyé, Principal Investigator (Data Coordinating Center)

Shelly Sayre, Project Manager (Data Coordinating Center) ?


Shelly Sayre, M.P.H.
Project Manager
Cardiovascular Cell Therapy Research Network
UT-Houston School of Public Health
1200 Pressler Street #E1013 
Houston, TX 77030
Ph. 713-500-9529, Fax 713-486-0981